Hainan Simcere Pharmaceutical Co. Ltd. has patented fibroblast growth factor receptor 3 (FGFR3) inhibitors reported to be useful for the treatment of cancer.

The University of Tokyo has synthesized yaku'amide B analogues reported to be useful for the treatment of cancer.

Takeda Pharmaceutical Co. Ltd. has discovered orexin OX2 receptor agonists reported to be useful for the treatment of narcolepsy, among others.

Tiger Biotherapeutics Inc. has disclosed proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase cereblon (CRBN)-binding moiety coupled to a GTPase KRAS (mutant)-binding moiety through a linker.

Work at Shanghai Meiyue Biotech Development Co. Ltd. has led to the discovery of spiro-heterocycle substituted pyrimidine compounds acting as C-C chemokine receptor type 4 (CCR4) antagonists.

Rewind Therapeutics NV has disclosed fused pyrrolyl-sulfonamide compounds acting as uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-like) antagonists.

Aexon Labs Inc. has identified dihydro-quinazoline, -benzothiazine and -benzoxazine derivatives acting as orexin receptors agonists. As such, they are reported to be possibly useful for the treatment of Parkinson’s disease, and type 1 and type 2 narcolepsy.

A Merck Sharp & Dohme LLC patent details new adenosine A2A and/or A2B receptor antagonists potentially useful for the treatment of cancer.

Accutar Biotechnology Inc. has patented new substituted quinoline derivatives acting as son of sevenless homolog 1 (SOS1) inhibitors reported to be useful for the treatment of cancer.

Janssen Pharmaceutica NV and Johnson & Johnson (China) Investment Ltd. patents disclose new menin (MEN1)/MLL interaction inhibitors reported to be useful for the treatment of cancer.